Intraglandular botulinum neurotoxin (BoNT) injection vs placebo injection: Reduction in frequency and severity of drooling
Type A botulinum toxin significantly reduced DSFS scores versus placebo (SMD -0.80, 95% CI -1.25 to -0.36; ungraded subgroup).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Botulinum toxin (BoNT) injection into salivary glands vs Placebo injection Drooling Severity and Frequency Scale (DSFS) score · Adults with Parkinson's disease and sialorrhea (drooling) · Approximately 1 month post-injection (one study ~1 week), Movement-disorder / neurology outpatient care (trials from Italy, USA, and Estonia), BoNT type A Type A botulinum toxin significantly reduced DSFS scores versus placebo (SMD -0.80, 95% CI -1.25 to -0.36; ungraded subgroup). The effectiveness and safety of botulinum toxin injections for the treatment of sialorrhea with Parkinson's… (2023) All outcomes | SMD -0.80 [-1.25, -0.36] | 4 studies · 88 participants | GRADE not reported |
Botulinum toxin (BoNT) injection into salivary glands vs Placebo injection Drooling Severity and Frequency Scale (DSFS) score · Adults with Parkinson's disease and sialorrhea (drooling) · Approximately 1 month post-injection (one study ~1 week), Movement-disorder / neurology outpatient care (trials from Italy, USA, and Estonia), BoNT type B Type B botulinum toxin significantly reduced DSFS scores versus placebo (SMD -1.11, 95% CI -1.48 to -0.74; ungraded subgroup); no significant difference between types A and B (p=0.30). The effectiveness and safety of botulinum toxin injections for the treatment of sialorrhea with Parkinson's… (2023) All outcomes | SMD -1.11 [-1.48, -0.74] | 5 studies · 136 participants | GRADE not reported |
Botulinum toxin (BoNT) injection into salivary glands vs Placebo injection Drooling Severity and Frequency Scale (DSFS) score · Adults with Parkinson's disease and sialorrhea (drooling) · Approximately 1 month post-injection (one study ~1 week), Movement-disorder / neurology outpatient care (trials from Italy, USA, and Estonia) Botulinum toxin injection reduces Drooling Severity and Frequency Scale scores versus placebo in Parkinson's disease sialorrhea (SMD -0.98, 95% CI -1.27 to -0.70; high certainty). The effectiveness and safety of botulinum toxin injections for the treatment of sialorrhea with Parkinson's… (2023) All outcomes | SMD -0.98 [-1.27, -0.70] | 9 studies · 224 participants | High |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| The effectiveness and safety of botulinum toxin injections for the treatment of sialorrhea with Parkinson's disease: a systematic review… 2023 All outcomes | April 2022 | 8 | Critically Low / Critically Low |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.